Biosense Webster, Inc., a worldwide leader in the diagnosis and treatment of cardiac arrhythmias, announced the launch of the new CARTO® 3 MEM (Multi-Electrode Mapping) Version in the United States.
“Multi-electrode mapping represents a significant advancement in mapping technology, allowing physicians to acquire multiple mapping points simultaneously with a high level of detail and CARTO® 3 System accuracy”
NEW Multi-Electrode Mapping Technology
The CARTO® 3 MEM Version is the latest advancement on the CARTO® 3 System platform. Based on market-leading electromagnetic technology, the new CARTO® 3 MEM Version provides a fast method for mapping and diagnosing arrhythmias, while using sensor-based MEM-enabled catheters to maintain a high degree of anatomical accuracy. The new PENTARAY® Nav Catheter is equipped with the electromagnetic sensor, allowing for accurate visualization of electrode position on the CARTO® 3 System and higher resolution signals.
"Multi-electrode mapping represents a significant advancement in mapping technology, allowing physicians to acquire multiple mapping points simultaneously with a high level of detail and CARTO® 3 System accuracy," said Dr. Vivek Reddy, Mount Sinai School of Medicine. "Combined with the new PENTARAY® Nav Catheter, you can reduce the number of required catheter maneuvers to quickly diagnose any arrhythmia. This further supports the safety, effectiveness and efficiency of cardiac ablation procedures for patients."
The real resolution limit of the human eye